الفهرس 
Title : Management and Outcome of Pediatric Retinoblastoma 10-year Single-center Experience
ContentsOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
To study the clinical presentation and survival outcome among children with retinoblastoma that were treated in pediatric oncology department at National Cancer Institute, Cairo University and to determine predictive factors of poor outcome and response to different treatment modalities
Methods: This retrospective study included patients diagnosed with retinoblastoma that were treated in the pediatric oncology department at National Cancer Institute, Cairo University during the period between January 2009 and December 2018. Demographic and clinical
characteristics and treatment outcomes were studied.
Results: A total of 48 patients (32 boys) with 59 eyes (unilateral 77.1%, bilateral 22.9%) were studied. The median age at presentation was 25.5 months and leukocoria was the most common symptom (47.5%), followed by proptosis (37.5%) Only one patient had positive family history and 22.9% had metastasis. Tumors were intraocular in 60.4% and extraocular in 39.6% of cases. CNS metastasis was noted in 10.8% of extraocular cases. In the intraocular group, 37.5% were group D and 9.4% were group E disease. During the study period, 21 patients (48.8%) died; with median follow-up (33.3) months. The cumulative (OS) was (89%) & (52%) at 1 & 3 years, respectively and cumulative (EFS) was (70.4%) & (46%) at 1 & 3 years, respectively. Factors correlated with inferior survival included extraocular disease (P =0.004), and delayed start of treatment > 6 months from onset of symptoms.
Conclusions: Outcome of RB is poor in our cohort. Delayed presentation is a matter of concern. Improving awareness about the early signs and creating facilities for diagnosing and treating RB are important to reduce mortality and morbidity, and improve outcome.